PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCapsaicin
Qutenza(capsaicin)
Qutenza (capsaicin) is a small molecule pharmaceutical. Capsaicin was first approved as Qutenza on 2009-05-15. It is used to treat diabetic neuropathies, herpes zoster, and neuralgia in the USA. It has been approved in Europe to treat neuralgia. The pharmaceutical is active against transient receptor potential cation channel subfamily V member 1. In addition, it is known to target voltage-gated potassium channel KCNC1, potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 2, cystic fibrosis transmembrane conductance regulator, and potassium voltage-gated channel subfamily A member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
nervous system diseasesD009422
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Qutenza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Capsaicin
Tradename
Company
Number
Date
Products
QUTENZAAveritas PharmaN-022395 RX2009-11-16
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
0.025% capsaicin pain relief patchC2002632025-06-10
1st medxpatchC2002632024-10-31
2-count heat patchesC2002632024-12-19
3% menthol plus 0.083% capsaicin pain relief patchC2002632025-06-10
advil targeted reliefC2002632024-02-08
ageranium patchOTC monograph not final2017-12-29
alivio medicated painOTC monograph not final2015-01-21
allevessOTC monograph not final2015-12-02
ameripatchOTC monograph not final2015-11-18
arth arrestC2002632023-11-11
Show 233 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
neuralgiaEFO_0009430D009437—
diabetic neuropathiesEFO_1000783D003929—
herpes zosterEFO_0006510D006562B02
Agency Specific
FDA
EMA
Expiration
Code
CAPSAICIN, QUTENZA, AVERITAS
2023-07-17I-838
Patent Expiration
Patent
Expires
Flag
FDA Information
Capsaicin, Qutenza, Averitas
88219202030-03-26DP
92269032028-12-15DP
100348412025-09-06DP
82630592023-09-05U-2705
88891132023-09-05U-2705
104635982023-09-05DP
108698272023-09-05DP
ATC Codes
M: Musculo-skeletal system drugs
— M02: Topical products for joint and muscular pain
— M02A: Topical products for joint and muscular pain
— M02AB: Capsaicin and similar agents
— M02AB01: Capsaicin
N: Nervous system drugs
— N01: Anesthetics
— N01B: Local anesthetics
— N01BX: Other local anesthetics in atc
— N01BX04: Capsaicin
HCPCS
Code
Description
J7336
Capsaicin 8% patch, per square centimeter
Clinical
Clinical Trials
283 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postherpetic neuralgiaD051474————1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Peripheral nervous system diseasesD010523—G641————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic neuropathiesD003929EFO_1000783—————11
Low back painD017116—M54.5————11
Back painD001416—M54————11
RadiculopathyD011843—M54.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCapsaicin
INNcapsaicin
Description
Capsaicin is a capsaicinoid. It has a role as a non-narcotic analgesic, a voltage-gated sodium channel blocker and a TRPV1 agonist.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
Identifiers
PDB—
CAS-ID404-86-4
RxCUI—
ChEMBL IDCHEMBL294199
ChEBI ID3374
PubChem CID1548943
DrugBankDB06774
UNII IDS07O44R1ZM (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TRPV6
TRPV6
KCNC1
KCNC1
Organism
Homo sapiens
Gene name
TRPV6
Gene synonyms
ECAC2
NCBI Gene ID
55503
Protein name
transient receptor potential cation channel subfamily V member 6
Protein synonyms
Alu-binding protein with zinc finger domain, Calcium transport protein 1, calcium transporter-like protein, CaT-L, CaT-like, CaT1, ECaC2, epithelial apical membrane calcium transporter/channel CaT1, Epithelial calcium channel 2
Uniprot ID
Q9H296
Mouse ortholog
Trpv6 (64177)
transient receptor potential cation channel subfamily V member 6 (Q91WD2)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Capsaicin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 37,785 documents
View more details
Safety
Black-box Warning
Black-box warning for: Capsinac, Diclosaicin, Diclotral pak, Flexipak, Iclofenac cp, Lextol, Naprotin, Ziclopro
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,939 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use